Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI346 in Relapsed/Refractory Multiple Myeloma
NCT05266768Phase 1Unknown
- Start
- Apr 2022
- Primary completion
- Feb 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IBI346 in multiple myeloma (MM). Primary endpoints: Dose limiting toxicity at 21 days, Incidence and severity of adverse events at 2 years and 1 more. Status: unknown.
02
Drugs
IBI346
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05266768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05266768.